- Conditions
- Type 2 Diabetes
- Interventions
- Placebo for Nasulin, Nasulin
- Other · Drug
- Lead sponsor
- CPEX Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Chandler, Arizona • Escondido, California • La Jolla, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 166
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 1,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Diabetes Mellitus
- Interventions
- Exenatide, Exenatide matching placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Insulin detemir, Dietary regimen
- Drug · Dietary Supplement
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Ozark, Alabama • Anaheim, California + 63 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- SAR342434, insulin lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • Denver, Colorado
- Conditions
- Type 2 Diabetes Treated With Insulin, Hypoglycemia, Primary Health Care, Polypharmacy
- Interventions
- Conversation Aid, Attention Control Educational Handout
- Behavioral · Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- San Francisco, California • San Leandro, California • Union City, California + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lixisenatide (AVE0010), Placebo, Insulin glargine, Pen auto-injector, Metformin, Thiazolidinedione (TZD)
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 23
- States / cities
- Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more
- Conditions
- Fatty Liver
- Interventions
- Polyunsaturated fatty acid (Opti-EPA), Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 60 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- semaglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 50
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Fountain Hills, Arizona + 44 more
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Efsitora Alfa, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Concord, California • Escondido, California + 34 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Peglispro, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Zephyrhills, Florida • Indianapolis, Indiana + 7 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 86
- States / cities
- Bay Minette, Alabama • Birmingham, Alabama • Huntsville, Alabama + 80 more
- Conditions
- Type 2 Diabetes
- Interventions
- INS068 injection, Insulin Degludec
- Drug
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Huntington Park, California • Lincoln, California • Lomita, California + 10 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY3209590, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Concord, California + 33 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
- Device
- Lead sponsor
- Calibra Medical, Inc.
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 18
- States / cities
- Fresno, California • Northridge, California • Miami, Florida + 14 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 46
- States / cities
- Little Rock, Arkansas • Concord, California • La Jolla, California + 43 more
- Conditions
- Type 2 Diabetes Mellitus, Obesity
- Interventions
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Procedure · Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Type 2 Diabetes Treated With Insulin
- Interventions
- Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS), Continuous Glucose Monitor (CGM) + Usual Care
- Other
- Lead sponsor
- Daniel Chernavvsky, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Insulin glargine U100
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 13
- States / cities
- Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine, Insulin Glulisine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chula Vista, California